transthyretin amyloidosis treatment market outlook, transthyretin amyloidosis treatment market key players, transthyretin amyloidosis treatment market demand, transthyretin amyloidosis treatment market size, transthyretin amyloidosis treatment market trends, transthyretin amyloidosis treatment market share analysis
What is the current size and annual growth rate of the transthyretin amyloidosis treatment market?
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.52 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.
The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines.
Get Your Free Sample of The Global Transthyretin Amyloidosis Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
Which major factors have contributed to the expansion of the transthyretin amyloidosis treatment market?
Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market going forward. Research and development (R&D) investments include financial resources allocated to activities aimed at advancing scientific knowledge, developing new technologies, creating innovative products, and improving existing processes. Increased funding in research and development enables the discovery and development of innovative treatment approaches for transthyretin amyloidosis, including novel drugs, gene therapies, and precision medicine techniques, offering patients more effective and targeted treatment options. For instance, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company engaged in the development of Vutrisiran, a treatment of ATTR amyloidosis, increased its research and development investment to $883,015 in 2022 from $792,156 in 2021, reflecting a growth of 11.49%. Therefore, the rising investment in research and development will drive the growth of the transthyretin amyloidosis treatment market.
How is the transthyretin amyloidosis treatment market segmented?
The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
Order your report now for swift delivery
Who are the top competitors in the transthyretin amyloidosis treatment market?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
Which key trends are expected to influence the transthyretin amyloidosis treatment market in the coming years?
Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022. `
Which regional trends are influencing the transthyretin amyloidosis treatment market, and which area dominates the industry?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Transthyretin Amyloidosis Treatment Market Report 2025 Offer?
The transthyretin amyloidosis treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal protein deposits in the body’s organs and tissues. Transthyretin amyloidosis treatment refers to the medical interventions and therapeutic strategies designed to manage and mitigate the effects of transthyretin amyloidosis (ATTR).
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
